LAG3 and synucleinopathy: Serum sLAG-3 levels in PD patients were significantly higher compared to healthy controls [128, 129], indicating that this interaction between LAG-3 and α-syn could provide a possible target for the development of therapeutics designed to slow the progression of α-synucleinopathies.